The study demonstrates topical treatment reduces pro-inflammatory cytokines in psoriasis via glycolic acid nanocarriers co-delivering apremilast and quercetin.
AIM: The goal of this study was to develop and optimize glycolic acid integrated nanostructured lipid carriers (NLCs). METHODS: skin permeation and retention analysis, cytocompatibility using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, antioxidant measurements via DPPH (2,2-diphenyl-1-picrylhydrazyl) scavenging assessment for anti-inflammatory effects by observing cytokine inhibition in lipopolysaccharide (LPS)-stimulated macrophages, and in-vivo irritation potential using the Hen's Egg Test on the Chorioallantoic Membrane (HET-CAM) assay were also evaluated. RESULTS: The optimized NLCs have a particle size of 121.75 ± 9.18 nm, a PDI of 0.367 ± 0.07, and a zeta potential of -35.77 ± 3.44 mV, indicating a stable formulation. In-vitro assays demonstrated sustained drug release, cytocompatibility, and antioxidant potency with effective reduction of pro-inflammatory cytokines, i.e. interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). CONCLUSION: The combined Apremilast (APM)-Quercetin (QRC)-NLC integrated with glycolic acid introduces an promising nanocarrier strategy for the topical treatment of psoriasis.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: